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Abstract
Background: The definite diagnosis of prion diseases such as Creutzfeldt-Jakob disease (CJD) in
humans or bovine spongiform encephalopathy (BSE) in cattle currently relies on the post mortem
detection of the pathological form of the prion protein (PrPSc) in brain tissue. Infectivity studies
indicate that PrPSc may also be present in body fluids, even at presymptomatic stages of the disease,
albeit at concentrations well below the detection limits of currently available analytical methods.
Results: We developed a highly sensitive method for detecting prion protein aggregates that takes
advantage of kinetic differences between seeded and unseeded polymerization of prion protein
monomers. Detection of the aggregates was carried out by flow cytometry. In the presence of
prion seeds, the association of labelled recombinant PrP monomers in plasma and serum proceeds
much more efficiently than in the absence of seeds. In a diagnostic model system, synthetic PrP
aggregates were detected down to a concentration of approximately 10-8 nM [0.24 fg/ml]. A specific
signal was detected in six out of six available serum samples from BSE-positive cattle.
Conclusion: We have developed a method based on seed-dependent PrP fibril formation that
shows promising results in differentiating a small number of BSE-positive serum samples from
healthy controls. This method may provide the basis for an ante mortem diagnostic test for prion
diseases.
Background
A group of fatal transmissible neurodegenerative diseases,
including Creutzfeld-Jakob disease (CJD), bovine spongi-
form encephalopathy (BSE), chronic wasting disease
(CWD) and scrapie, is caused by an unusual infectious
agent that has been termed prion [1]. Prions consist of an
aberrant isoform (PrPSc) of the normal cellular prion pro-
tein (PrPC). PrPC is a cell surface glycoprotein expressed in
neurons [2] and other cell types [3,4]. The precise physio-
logical function of the cellular prion protein is not known
yet. PrPSc differs from PrPC in its higher content of β-sheet
structure [5,6], its partial resistance to protease digestion
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[7], and its tendency to form large aggregates [8]. PrPSc
propagates by converting the cellular prion protein to the
PrPSc conformation [9]. PrPSc aggregates accumulate pre-
dominantly in the central nervous system (CNS), and
definitive diagnosis of prion diseases currently relies on
the post mortem detection of PrPSc in CNS tissue by immu-
nohistochemistry, Western blotting, or ELISA [10]. Trans-
mission studies indicate that prions may also be present
in blood, potentially allowing for ante mortem diagnosis,
but the sensitivity of the currently available analytical
methods is insufficient for the detection of the extremely
low prion titers that can be expected in body fluids [11].
Here, we report the development of a method based on
kinetic differences between seeded and unseeded aggrega-
tion of prion protein that allows the detection of PrP
aggregates in blood down to attomolar concentrations by
flow cytometry.
Results and discussion
Detection of synthetic prion protein aggregates in serum 
or plasma
Kinetic differences between seeded and spontaneous
polymerization of peptide monomers can be used for the
detection of amyloid β-protein aggregates in the cerebros-
pinal fluid of Alzheimer's disease patients [15]. Here, we
extend the principle of seeded polymerization to the
detection of prion protein aggregates.
While trying to establish conditions for the labeling of
synthetic prion protein aggregates with a fluorescently
labeled prion protein probe, we observed that the forma-
tion of prion protein aggregates proceeds much less effi-
ciently in serum or plasma (not shown) than in PBS (Fig.
1). This inhibition is probably caused by interactions of
the prion protein probe with serum proteins.
Next, we found that the addition of preformed prion pro-
tein aggregates to plasma can partially overcome this inhi-
bition (Fig. 2). The preformed aggregates presumably
function as seeds that facilitate the formation of new
aggregates in the inhibitory environment of plasma. The
seeds stimulated the formation of prion protein aggre-
gates at all concentrations tested, from 5 nM [120 ng/ml]
to 10-8 nM [0.24 fg/ml] (Fig 2C). The average ratio of
event counts in seeded samples to those in samples with-
out seeds was 6.4. The number of events, however, was
not proportional to the seed concentration, but remained
relatively constant over the whole concentration range.
Thus, the seed-dependent formation of prion protein
aggregates can be used to detect extremely low amounts
(down to the attomolar range) of spiked prion protein
aggregates in blood.
Inhibition of PrP aggregation in serum Figure 1
Inhibition of PrP aggregation in serum. FITC-labeled recombinant bovine prion protein (concentration 10 nM) was incu-
bated at 37°C for 20 h with continuous shaking, either in 150 µl PBS (left panel) or in the same volume of serum (right panel), 
followed by flow cytometry. The measurements are depicted in a Fluorescence 1 (FL1-H) vs. Fluorescence 2 (FL2-H) dot-plot. 
The number of counts in the area containing specific signals (R2) is given in the figures. Aggregate formation in serum is 
strongly inhibited.
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Analysis of serum from clinical-stage, BSE-positive cattle
Studies demonstrating the transmission of prion diseases
by blood transfusion suggest that prions are present in the
blood of afflicted animals and people, even at pre-symp-
tomatic stages of the disease [16-18]. We used the method
of seed-dependent fibril formation to analyze serum from
six confirmed cases of clinical-stage, BSE-positive cattle
and four controls. Based on the spiking experiments
described above, our hypothesis was that any PrPSc aggre-
gates present in serum may act as seeds for the formation
of easily detectable amounts of labeled PrP aggregates,
whereas in the absence of seeds the formation of PrP
aggregates would be inhibited. The serum samples from
BSE-positive cattle and controls from healthy cattle were
incubated with 10 nM of a FITC-labeled bovine PrP probe
at 37°C for 20 h with continuous shaking, followed by
analysis in a flow cytometer. All six BSE-samples could be
clearly distinguished by a population of events that was
absent in the controls (Fig. 3A–J, green dots in region R3;
quantification in fig. 3K).
Conclusion
We have developed a method based on seed-dependent
PrP fibril formation that shows promising results in differ-
entiating a small number of BSE-positive serum samples
from healthy controls. More samples need to be tested in
order to validate its potential as an ante mortem diagnostic
test for BSE and other prion diseases.
Methods
Biological fluids
Serum samples from six confirmed cases of BSE in cattle
and four control animals were obtained from BFAV, Insel
Riems, Germany. Control plasma was obtained from a
blood bank.
Labeling of prion protein
Recombinant full-length bovine PrP was produced as
described previously [12,13]. The purified protein was
labeled with a FITC-labeling kit (Roche) according to the
manufacturer's instructions.
Preparation of fibrils from recombinant prion protein
25 µM of unlabeled bovine prion protein in PBS contain-
ing 0.2 % SDS was incubated for 10 min at room temper-
ature, followed by a twentyfold dilution with PBS. For
fibril formation, the diluted reaction mixture was incu-
bated for 48 h at room temperature [14].
PrP fibril formation in serum or plasma
Recombinant FITC-labeled bovine prion protein was
incubated in 150 µl serum or plasma at a concentration of
5 or 10 nM for 5–10 min. at 20°C, shaking at 550 rpm in
an Eppendorf thermomixer, followed by an increase of
the temperature to 37°C h at constant shaking speed. The
incubation was continued for 20 h. Samples were then
analyzed by flow cytometry.
Flow cytometry
Analysis of the samples was carried out on a FACSVantage
flow cytometer (BD Biosciences) at room temperature,
measurement time was 30 sec per sample.
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Seed-dependent PrP aggregate formation in plasma Figure 2
Seed-dependent PrP aggregate formation in plasma. FITC-labeled recombinant prion protein (5 nM) was incubated in 
plasma as described in the methods section for 20 h either in the absence (panel A) or presence (panel B) of 10-8 nM PrP aggre-
gates. Panel C: quantification of measurements shown in A and B, and of measurements (not shown) with different seed con-
centrations. The measurements are depicted in a Fluorescence 1 (FL1-H) vs. Side-Scatter (SSC) dot-plot. Aggregate formation 
(signal in region R1) was strongly enhanced by all seed concentrations tested, from 5 nM to 10-8 nM.
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Analysis of serum from BSE-positive cattle Figure 3
Analysis of serum from BSE-positive cattle. FITC-labeled recombinant prion protein (10 nM) was incubated in 150 µl of 
the serum samples as described in the methods section and analyzed by flow cytometry. The measurements are shown in a Flu-
orescence 1 (FL1-H) vs. Side-Scatter (SSC) dot-plot. All six BSE-samples (A-F) can be differentiated from the controls (G-J) by 
a population of events in region R3 (green dots). Panel K: Quantification of measurements shown in panels A-J.
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